Sangamo Therapeutics (NASDAQ:SGMO) and X4 Pharmaceuticals (NASDAQ:XFOR) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, risk, valuation, profitability, earnings, analyst recommendations and institutional ownership.
Insider and Institutional Ownership
57.2% of Sangamo Therapeutics shares are held by institutional investors. Comparatively, 14.4% of X4 Pharmaceuticals shares are held by institutional investors. 1.3% of Sangamo Therapeutics shares are held by insiders. Comparatively, 4.9% of X4 Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
This table compares Sangamo Therapeutics and X4 Pharmaceuticals’ net margins, return on equity and return on assets.
||Return on Equity
||Return on Assets
Risk & Volatility
Sangamo Therapeutics has a beta of 2.99, meaning that its stock price is 199% more volatile than the S&P 500. Comparatively, X4 Pharmaceuticals has a beta of 1.9, meaning that its stock price is 90% more volatile than the S&P 500.
Earnings and Valuation
This table compares Sangamo Therapeutics and X4 Pharmaceuticals’ gross revenue, earnings per share and valuation.
||Earnings Per Share
X4 Pharmaceuticals has lower revenue, but higher earnings than Sangamo Therapeutics.
This is a breakdown of current ratings and price targets for Sangamo Therapeutics and X4 Pharmaceuticals, as provided by MarketBeat.com.
||Strong Buy Ratings
Sangamo Therapeutics presently has a consensus price target of $13.33, suggesting a potential upside of 11.11%. X4 Pharmaceuticals has a consensus price target of $27.00, suggesting a potential upside of 81.82%. Given X4 Pharmaceuticals’ stronger consensus rating and higher possible upside, analysts plainly believe X4 Pharmaceuticals is more favorable than Sangamo Therapeutics.
X4 Pharmaceuticals beats Sangamo Therapeutics on 7 of the 12 factors compared between the two stocks.
About Sangamo Therapeutics
Sangamo Therapeutics, Inc. focuses on translating science into genomic medicines that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy. The company's zinc finger proteins (ZFPs) could be engineered to make zinc finger nucleases (ZFNs), proteins that could be used to modify DNA sequences by adding or knocking out specific genes or genome editing; and ZFP transcription factors (ZFP TFs) proteins that can be used to increase or decrease gene expression or gene regulation. Its therapeutic products which are in Phase I/II clinical trial include SB-525 for the treatment of hemophilia A; SB-FIX for the treatment of hemophilia B; ST-400 for the treatment of beta-thalassemia; and SB-318 for the treatment of Mucopolysaccharidosis Type I and SB-913 for the treatment of Mucopolysaccharidosis Type II, which are lysosomal storage disorders (LSDs). The company also develops ST-920, a gene therapy for fabry disease. It has collaboration and license agreements with Kite Pharma, Inc., Pfizer Inc., Bioverativ Inc., and Shire International GmbH, as well as license partnerships with Dow AgroSciences LLC, Sigma-Aldrich Corporation, Genentech, Inc., Open Monoclonal Technology, Inc., F. Hoffmann-La Roche Ltd, and Hoffmann-La Roche Inc. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was founded in 1995 and is headquartered in Richmond, California.
About X4 Pharmaceuticals
X4 Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for the treatment of primary immune-deficiencies and cancer. Its lead drug candidate is mavorixafor (X4P-001), an oral small molecule antagonists of chemokine receptor CXCR4, which is in Phase I clinical trial to treat severe congenital neutropenia; Phase I/II clinical trial for the treatment of Waldenström macroglobulinemia; and Phase IIa clinical trial to treat clear cell renal cell carcinoma, as well as that has completed Phase II clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome. The company is also developing X4P-002 for the treatment of glioblastoma multiforme; and X4P-003 to treat primary immune-deficiencies. The company was formerly known as Arsanis, Inc. and changed its name to X4 Pharmaceuticals, Inc. in March 2019. X4 Pharmaceuticals, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.
Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.